9hon MSN
We recently published a list of 13 Most Undervalued NASDAQ Stocks To Buy According To Hedge Funds. In this article, we are ...
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
In recognition of Women's History Month, our Identity + Innovation spotlight features Devi SenGupta. Hear how Devi's background has shaped her approach to developing new medicines and to bringing ...
Weeks after settling a five-year patent dispute with the U.S. | Gilead set aside approximately $200 million for a potential ...
Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
FOSTER CITY, Calif., March 12, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment ...
Gilead Sciences (NASDAQ:GILD – Get Free Report) had its target price upped by Wells Fargo & Company from $120.00 to $140.00 ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results